Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
NCT Number:
NCT04696029
Phase:
II
Protocol Type:
Treatment
Age Group:
Children
Disease Sites:
Brain and Nervous System
Study Objectives:
To evaluate the efficacy of difluoromethylornithine (DFMO) as a single agent in preventing relapse in patients with molecular high risk and very high risk medulloblastoma, and relapsed/refractory medulloblastoma based upon the 2-year progression-free survival rate (PFS) compared to relevant historical controls.
Study Documents
(MUSC NetID required for document access)